登录 | 注册    关注公众号  
微信公众号
搜索
 >  Kits>Spike protein >RAS-A039

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)

For research use only.

组分(Materials Provided)

IDComponentsSize
RAS039-C01Pre-coated Anti-SARS-CoV-2 Spike Protein Antibody Microplate1 plate
RAS039-C02SARS-CoV-2 Spike Protein10 ug
RAS039-C03HRP-Anti-SARS-CoV-2 Spike Protein Antibody20 ug
RAS039-C0410xWashing Buffer 50 mL
RAS039-C05Dilution Buffer50 mL
RAS039-C06Substrate Solution12 mL
RAS039-C07Stop Solution7 mL

产品概述(Product Overview)

The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

应用说明(Application)

This kit is developed for detecting SARS-CoV-2 Spike Protein in vaccine samples,which is the low sensitivity version of Cat.No. RAS-A020.The kit can meet the needs of vaccine developers to establish antigen quantification methods for preclinical evaluation, vaccine production and quality control, and realize accurate quantification of vaccine antigen contents for COVID-19 vaccines of all technological platforms, multivalent vaccines, and VOC-specific boosters.

It is for research use only.

重构方法(Reconstitution)

Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.

存储(Storage)

原理(Assay Principles)

This assay kit employs a standard sandwich-ELISA format, providing a rapid detection of SARS-CoV-2 Spike Protein. The kit consists of microplate pre-coated with Anti-SARS-CoV-2 Spike protein Antibody, an SARS-CoV-2 Spike Protein as Control, an HPR-Anti-SARS-CoV-2 Spike protein Antibody,and buffers.

Your experiment will include 5 simple steps:

a) All reagents were returned to room temperature (20°C-25°C) before use.

b) Add your sample to the plate, take the SARS-CoV-2 Spike protein as Control sample. The samples and Control sample are diluted by Dilution Buffer.

c) Add a diluted HRP-Anti-SARS-CoV-2 Spike Protein Antibody to the plate. The diluted by Dilution Buffer.

d) Wash the plate and add TMB.

e) Stop the substrate reaction by add diluted acid. Absorbance (OD) is calculate as the absorbance at 450 nm minus the absorbance at 630 nm to remove background prior to statistical analysis. The OD Value reflects the amount of protein bound.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

典型数据-Typical Data Please refer to DS document for the assay protocol.

Spike protein TYPICAL DATA

Immobilized Anti-SARS-CoV-2 Spike Protein Antibody at 2 μg/mL (100 μL/well) can bind SARS-CoV-2 Spike Protein. Detection was performed using HRP-Anti-SARS-CoV-2 Spike Protein Antibody with sensitivity of 20 ng/mL (QC tested).

Spike protein TYPICAL DATA

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)(Cat.No.RAS-A039) can potently to detect the all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (Cat.No.SPN-C52H6), Beta (Cat.No.SPN-C52Hk), Gamma (Cat.No.SPN-C52Hg) and Delta (Cat.No.SPN-C52He).

Spike protein TYPICAL DATA

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development) (Cat.No.RAS-A039) can potently to detect the all SARS-CoV-2 Variants of Concern (VOCs), including Omicron (Cat.No.SPN-C52Hz).

 
评论(1)
 
ACRO质量管理体系
 
 

前沿进展

Electroconvulsive Therapy in Cochlear Implant Users
Crotty, Alshehri, Gendre et al
J ECT (2025)
Abstract: Cochlear implant manufacturers currently contraindicate the use of electroconvulsive therapy (ECT) in CI users, citing theoretical evidence of potential harm to the patient or the implant despite a lack of clinical data. We report two uncomplicated cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral CIs.The first case involves a 66-year-old visually impaired male with bilateral CIs. He suffered from major depressive disorder complicated by refusal of oral intake despite maximal pharmacological therapy. He underwent 9 consecutive cycles of bilateral ECT, after which his psychiatric condition improved. Cochlear implant function remained unchanged following the procedure. The second case involved a 65-year-old female with a left-sided CI and a history of recurrent depressive disorder. Her condition deteriorated with the onset of auditory hallucinations and increased suicidality. She underwent 8 consecutive cycles of unilateral ECT with right-sided electrode placement. Her psychiatric condition improved, and there was no change in CI impedance following the procedure.We report 2 successful cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral cochlear implants. Further investigation into the safety of ECT in CI users is warranted to ensure that this crucial treatment modality remains available to this vulnerable patient cohort.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Design of Porous 3D Interdigitated Current Collectors and Hybrid Microcathodes for Zn-Ion Microcapacitors
Fan, Naresh, Zhu et al
ACS Nano (2025)
Abstract: Zinc-ion microcapacitors (ZIMCs) have gained considerable attention for their intrinsic charge storage mechanisms, combining a battery-type anode with a capacitor-type cathode. However, their development is constrained by challenges related to electrode material selection and microscale device design, especially given the limited footprint of such devices. Despite their potential, exploration of smart electrode processing and hybrid materials for on-chip ZIMCs remains limited. In this work, we introduce 3D gold interdigitated electrodes (3D Au IDEs) as highly porous current collectors, loaded with zinc (Zn) as the anode and hybrid activated carbon coated with PEDOT (AC-PEDOT) as the cathode, using an advanced microplotter fabrication technique. Compared with planar Zn//AC ZIMCs, where Zn and AC materials are loaded onto planar Au IDEs, the 3D Au Zn//AC-PEDOT ZIMCs demonstrate significantly enhanced performance. This is attributed to the critical role of IDEs in increasing the charge storage capacity, improving long-term cycling stability, and boosting capacitive-controlled charge storage contributions. The 3D Au Zn//AC-PEDOT ZIMCs achieve an areal capacity of 1.3 μAh/cm2, peak areal energy of 1.11 μWh/cm2, and peak areal power of 640 μW/cm2, surpassing most reported microsupercapacitors. This study highlights how optimized collectors and hybrid electrodes enhance microdevice charge storage while maximizing performance within a constrained footprint.
Protocol for evaluating neuronal activity and neurotransmitter release following amyloid-beta oligomer injections into the rat hippocampus
Hervé, Bonenfant, Amyot et al
STAR Protoc (2025) 6 (2), 103712
Abstract: In Alzheimer's disease, there is an imbalance in neurotransmitter release and altered neuronal activation. Here, we present a protocol approach to analyze neuronal activity by combining local field potential (LFP) recording with microdialysis within the same animal. We describe steps for measuring glutamate and GABA levels following hippocampal amyloid-beta oligomer (Aβo) injections in rats. We then detail procedures for assembling the electrode and cannula, surgical implantation and simultaneous in vivo LFP recording, interstitial fluid collection, and Aβo injections.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Can Difluoroethylene Carbonate Replace Fluoroethylene Carbonate for High-Performance Lithium-Ion Cells at High Voltage?
Guan, Ouyang, Wan et al
ACS Appl Mater Interfaces (2025)
Abstract: To date, optimizing electrolytes has become a promising approach to enable high-voltage, high-performance lithium-ion cells. Herein, a study is performed to evaluate the potential of difluoroethylene carbonate (DFEC) to replace fluoroethylene carbonate (FEC) and deliver comparable or even superior performance at high voltage. It is unveiled that moderately increasing lithium salt inside the DFEC-based electrolyte enhances the high-voltage performance of cells, with the DFEC-based electrolyte outperforming the FEC-based counterpart. Moreover, the DFEC-based electrolyte also fits the LiFePO4 system where a high performance is illustrated when charged to 3.8 and 4.0 V. As a result of the low binding energy between DFEC and Li+, an anion-rich solvation structure is formed by the DFEC-based electrolyte, facilitating Li+ intercalation/deintercalation and forming inorganic-rich passivation layers. In addition, the cell's electrode-electrolyte interface is well-protected due to the superior film property of DFEC, where a thin, smooth, and robust passivation layer is generated that efficiently prevents the electrode and electrolyte from side reactions under high voltage. Furthermore, the DFEC-based electrolyte and the cells containing it also demonstrate superior safety properties when exposed to typical safety testing. Hence, DFEC is shown to be a viable alternative to FEC for enabling sound-performance lithium-ion cells at a high voltage.
Showing 1-4 of 310892 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Spike protein靶点信息
英文全称:Coronavirus spike glycoprotein
中文全称:冠状病毒刺突糖蛋白
种类:Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
上市药物数量:10详情
临床药物数量:72详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定